

Sarah Shigdar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1477973/publications.pdf>

Version: 2024-02-01

59
papers

3,073
citations

172457

29
h-index

155660

55
g-index

60
all docs

60
docs citations

60
times ranked

4952
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer stem cells: A contentious hypothesis now moving forward. <i>Cancer Letters</i> , 2014, 344, 180-187.	7.2	217
2	RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. <i>Cancer Science</i> , 2011, 102, 991-998.	3.9	199
3	Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine. <i>Theranostics</i> , 2015, 5, 23-42.	10.0	184
4	RNA aptamers targeting cancer stem cell marker CD133. <i>Cancer Letters</i> , 2013, 330, 84-95.	7.2	157
5	Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 2736-2748.	2.8	155
6	Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. <i>International Journal of Nanomedicine</i> , 2013, 8, 4103.	6.7	155
7	Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors. <i>Theranostics</i> , 2015, 5, 1083-1097.	10.0	147
8	Cancer stem cell targeted therapy: progress amid controversies. <i>Oncotarget</i> , 2015, 6, 44191-44206.	1.8	129
9	CD44 variant 6 is associated with prostate cancer metastasis and chemo/radioresistance. <i>Prostate</i> , 2014, 74, 602-617.	2.3	126
10	Inflammation and cancer stem cells. <i>Cancer Letters</i> , 2014, 345, 271-278.	7.2	105
11	Aptamers as Theranostic Agents: Modifications, Serum Stability and Functionalisation. <i>Sensors</i> , 2013, 13, 13624-13637.	3.8	104
12	EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. <i>Theranostics</i> , 2015, 5, 1456-1472.	10.0	84
13	Challenges and opportunities for siRNA-based cancer treatment. <i>Cancer Letters</i> , 2017, 387, 77-83.	7.2	82
14	Development of a Bifunctional Aptamer Targeting the Transferrin Receptor and Epithelial Cell Adhesion Molecule (EpCAM) for the Treatment of Brain Cancer Metastases. <i>ACS Chemical Neuroscience</i> , 2017, 8, 777-784.	3.5	75
15	Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. <i>International Journal of Nanomedicine</i> , 2014, 9, 1083.	6.7	72
16	Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. <i>Theranostics</i> , 2017, 7, 4071-4086.	10.0	70
17	Role of the EpCAM (CD326) in prostate cancer metastasis and progression. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 779-791.	5.9	68
18	Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. <i>Nanoscale</i> , 2015, 7, 14080-14092.	5.6	68

#	ARTICLE	IF	CITATIONS
19	Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic Applications?. <i>Molecules</i> , 2019, 24, 4377.	3.8	65
20	Fabrication of high specificity hollow mesoporous silica nanoparticles assisted by Eudragit for targeted drug delivery. <i>Journal of Colloid and Interface Science</i> , 2015, 445, 151-160.	9.4	59
21	Truncation and Mutation of a Transferrin Receptor Aptamer Enhances Binding Affinity. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 348-354.	3.6	56
22	Aptamers: Cutting edge of cancer therapies. <i>Molecular Therapy</i> , 2021, 29, 2396-2411.	8.2	52
23	EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. <i>Cancers</i> , 2018, 10, 19.	3.7	46
24	Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 117-128.	3.6	41
25	The Use of Sensitive Chemical Antibodies for Diagnosis: Detection of Low Levels of Epcam in Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e57613.	2.5	40
26	Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells. <i>Scientific Reports</i> , 2017, 7, 5898.	3.3	40
27	Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures. <i>Molecules</i> , 2017, 22, 2070.	3.8	35
28	Cytochemical characterisation of the leucocytes and thrombocytes from Murray cod (<i>Maccullochella peelii peelii</i> , Mitchell). <i>Fish and Shellfish Immunology</i> , 2009, 26, 731-736.	3.6	33
29	Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging. <i>Therapeutic Delivery</i> , 2012, 3, 227-244.	2.2	32
30	Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2576.	4.1	31
31	Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. <i>British Journal of Haematology</i> , 2011, 155, 3-13.	2.5	30
32	Enhanced Antitumor Efficacy and Reduced Systemic Toxicity of Sulfatide-Containing Nanoliposomal Doxorubicin in a Xenograft Model of Colorectal Cancer. <i>PLoS ONE</i> , 2012, 7, e49277.	2.5	29
33	The Application of Aptamers for Immunohistochemistry. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 120-126.	3.6	22
34	Antibodies, Nanobodies, or Aptamers-Which Is Best for Deciphering the Proteomes of Non-Model Species?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2485.	4.1	22
35	Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. <i>Pharmacological Research</i> , 2022, 175, 106019.	7.1	20
36	Aptamer-Mediated Cancer Gene Therapy. <i>Current Gene Therapy</i> , 2015, 15, 109-119.	2.0	18

#	ARTICLE	IF	CITATIONS
37	Aptamers as potential therapeutic agents for ovarian cancer. <i>Biochimie</i> , 2018, 145, 34-44.	2.6	17
38	Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof. <i>Pharmaceutics</i> , 2022, 14, 28.	4.5	17
39	Blood cells of Murray cod <i>Maccullochella peelii peelii</i> (Mitchell). <i>Journal of Fish Biology</i> , 2007, 70, 973-980.	1.6	16
40	Improved Efficacy and Reduced Toxicity of Doxorubicin Encapsulated in Sulfatide-Containing Nanoliposome in a Glioma Model. <i>PLoS ONE</i> , 2014, 9, e103736.	2.5	16
41	Radiolabelled Aptamers for Theranostic Treatment of Cancer. <i>Pharmaceutics</i> , 2019, 12, 2.	3.8	15
42	TaqIB polymorphism in the CETP gene modulates the impact of HC/LF diet on the HDL profile in healthy Chinese young adults. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 1114-1119.	4.2	14
43	Functional interaction between mutations in the granulocyte colony-stimulating factor receptor in severe congenital neutropenia. <i>British Journal of Haematology</i> , 2008, 142, 653-656.	2.5	12
44	Elevated Levels of Triglyceride and Triglyceride-Rich Lipoprotein Triglyceride Induced by a High-Carbohydrate Diet Is Associated with Polymorphisms of ϵ -APOA5-1131T>C and ϵ -APOC3-482C>T in Chinese Healthy Young Adults. <i>Annals of Nutrition and Metabolism</i> , 2011, 58, 150-157.	1.9	12
45	Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6163.	4.1	12
46	The control of epidermal growth factor grafted on mesoporous silica nanoparticles for targeted delivery. <i>Journal of Materials Chemistry B</i> , 2015, 3, 6094-6104.	5.8	10
47	Mesoporous silica nanorods toward efficient loading and intracellular delivery of siRNA. <i>Journal of Nanoparticle Research</i> , 2018, 20, 1.	1.9	10
48	Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options. <i>Drug Discovery Today</i> , 2022, 27, 1298-1314.	6.4	10
49	Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 18, 976-989.	2.4	8
50	Novel Detection of Nasty Bugs, Prevention Is Better than Cure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 149.	4.1	7
51	Aptamer-Based Diagnostics and Therapeutics. <i>Pharmaceutics</i> , 2019, 12, 6.	3.8	6
52	Groundwater pre-treatment prevents the onset of chronic ulcerative dermatopathy in juvenile Murray cod, <i>Maccullochella peelii peelii</i> (Mitchell). <i>Aquaculture</i> , 2011, 312, 19-25.	3.5	5
53	Modelling of mass transport and distribution of aptamer in blood-brain barrier for tumour therapy and cancer treatment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 173, 121-131.	4.3	5
54	What potential do aptamers hold in therapeutic delivery?. <i>Therapeutic Delivery</i> , 2017, 8, 53-55.	2.2	4

#	ARTICLE	IF	CITATIONS
55	Application of Aptamers in Histopathology. <i>Methods in Molecular Biology</i> , 2016, 1380, 191-196.	0.9	3
56	Ethosomes the Best Approach for Deeper Delivery of Drugs Through Transdermal Port: From Preparation to Biomedical Applications. <i>Journal of Colloid Science and Biotechnology</i> , 2015, 4, 87-98.	0.2	2
57	Efficacy of promising flavonoids from <i>Festuca</i> , <i>Lonicera</i> , and <i>Acacia</i> genera against glioblastoma multiforme; potential for the Dandenong Ranges. , 2020, , 383-422.		1
58	Cytokine Networks and Cancer Stem Cells. , 2015, , 67-87.		1
59	Cancer Stem Cells – Perspectives and How to Target Them. , 0, , .		0